3 research outputs found
Nuclear Factor Erythroid-2 Linked Factor (Nrf2) as a Potential Mediator of Hepatotoxicity
Hepatotoxicity is a term used to describe serious health complications of liver disease caused by a variety of factors. Nuclear factor erythroid-2 linked factor (Nrf2) as a potential mediator of hepatotoxicity via inflammatory and induction of oxidative stress, oxidation
produces more toxic compounds caused more pathogenic cases; therefore, to maintain sufficient homeostasis, involve antioxidant materials and detoxification factors. Controlling cytokine activity in normal cells is a useful way to regulate the signaling pathway of Nrf2. Recent studies found a relation between each Nrf2 and NF-κB activation and drug-induced liver injury. This review presents a detailed and conformation update of Nrf2 roles in hepatotoxicity which considers that drug-induced liver injury is the main problem to draw attention in medical clinics and to develop new drugs with less harmful to the liver. In addition to that. Kept each of normal oxidation and cytokines levels is crucial responses for cells alteration and remaining to survive
Histopathological Study of Liraglutide on Renal Deterioration Progression Induced by Doxorubicin
Podocyte injury is a major factor in many renal diseases leading to proteinuria that causes the risk of developing kidney deterioration. Glomerulosclerosis and tubulointerstitial fibrosis are the main histopathological feature as consequence of inflammation and apoptosis a result of
Â
long period of tubular protein load. Liraglutide an incretin hormone (GLP-1) analogue has effective as glycemic control in patient with type 2 diabetes. In recent years, liraglutide appear protected mechanism against inflammation and apoptosis for many tissues through GLP-1 receptor (GLP-1R) activation unrelated with glycemic control. 36 animal Wister rats used in this experiment, first group include 12 rats set as control group received just the normal saline, while second group include 24 rats induced podocyte injury by doxorubicin single dose and third group treated either normal saline or liraglutide (200 µg /kg/day I.P) for 28 days. Histopathological study is used to assess the protected effect of liraglutide on podocyte injury induced in male rats through three main histopathological changes (glomerulosclerosis, tubular damage, inflammatory infiltration) by Hematoxylin and eosin staining. In this study treatment group(C) with liraglutide appeared significant decreased (P< 0.05) in glomerulosclerosis, tubulointerstitial, and inflammatory infiltration after 28 day of treatment. In conclusion, liraglutide is effective in reducing inflammation and apoptosis which associate with chronic renal development as well as renoprotection by glycemic control which is indirectly effect
Role of miRNA in drug-induced hepatic injury
Acute liver disease is characterized by loss of liver function within days or weeks however, in the patient who is not previously diagnosed, its less common compared with chronic liver failure, which developed slowly and irreversible process. It’s caused by
Â
drug-induced liver damage (DILI) therefore identifying liver injury is challenging for clinical treatment and diagnosis. The major causes of liver failure involve toxic metabolites of some medications that consumed Adenosine Tri Phosphate (ATP) compared with normal conditions and increased oxidative stress due to overexpression of MicroRNAs, it is necessary to do complete diagnosis of patients. Biomarker parameters can be utilized to validate liver damage like microRNAs (miRNAs) analysis, it is a more receptive marker because increased earlier than the transaminases enzymes allowing for a more accurate diagnosis. we summarized recent signs of progress disease concerning the role of miRNA as a novel DILI biomarker, the miRNA levels can be measured in plasma, saliva, urine, fetal fluid (amniotic), as well as other materials either in human or animals like mice, rats which significantly elevate during illness, therefore, provide e specific biomarker of hepatoinjury